Sato S, Yamanaka T, Kimura K
Rinsho Byori. 1989 Nov;37(11):1259-62.
Tumor associated carbohydrate antigen TAC-41 identified by the monoclonal antibody against a gastric adenocarcinoma cell line. We evaluated the serum levels of TAC-41 in 55 patients with various malignancies and 44 patients with benign diseases, and compared them with the serum levels of other tumor markers including CA 19-9 and CA-50. When the normal range of serum TAC-41 level was less than 40 dilution titer, the positive rate for malignancies of TAC-41 was 100% in pancreas cancer, 80% in biliary tract cancer and 87% in hepatocellular carcinoma. On the other hand, specificity (64%) of TAC-41 in all patients was less than that of other tumor markers. However, efficiency (68%) of TAC-41 was no less than those of other tumor markers. Comparison of the serum levels of TAC-41 with CA 19-9 or CA-50 in the same samples revealed a highly positive correlation (r = 0.891) in patients with various cancers. These results indicate that TAC-41 is clinically no less useful than CA 19-9 or CA-50 as a tumor marker. The usefulness of this method is characterized by its short turnaround time and lower cost than other tumor markers. Eventually, TAC-41 is one of the most useful tumor marker in mass screening for digestive malignant diseases.
通过针对胃腺癌细胞系的单克隆抗体鉴定出肿瘤相关碳水化合物抗原TAC-41。我们评估了55例各种恶性肿瘤患者和44例良性疾病患者血清中TAC-41的水平，并将其与包括CA 19-9和CA-50在内的其他肿瘤标志物的血清水平进行比较。当血清TAC-41水平的正常范围小于40稀释滴度时，胰腺癌中TAC-41对恶性肿瘤的阳性率为100%，胆管癌中为80%，肝细胞癌中为87%。另一方面，TAC-41在所有患者中的特异性（64%）低于其他肿瘤标志物。然而，TAC-41的有效性（68%）不低于其他肿瘤标志物。对同一样本中TAC-41与CA 19-9或CA-50的血清水平进行比较，发现在各种癌症患者中存在高度正相关（r = 0.891）。这些结果表明，作为一种肿瘤标志物，TAC-41在临床上与CA 19-9或CA-50同样有用。该方法的有用性体现在其周转时间短且成本低于其他肿瘤标志物。最终，TAC-41是消化系统恶性疾病大规模筛查中最有用的肿瘤标志物之一。
